FDA adjusts ziprasidone labeling over risk of skin condition

Publisher： John Wiley & Sons Inc

E-ISSN： 1556-7532|26|3|8-8

ISSN： 1068-5308

Source： THE BROWN UNIVERSITY PSYCHOPHARMACOLOGY UPDATE, Vol.26, Iss.3, 2015-03, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

FDA approves labeling update for extended‐release aripiprazole

By  

THE BROWN UNIVERSITY PSYCHOPHARMACOLOGY UPDATE, Vol. 26, Iss. 2, 2015-02 ,pp. : 8-8

John Wiley & Sons Inc

Access to resources Recommend Favorite

FDA revises labeling to limit pediatric use of prescription cough and cold medicines

By  

THE BROWN UNIVERSITY CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY UPDATE, Vol. 20, Iss. 2, 2018-02 ,pp. : 8-8

John Wiley & Sons Inc

Access to resources Recommend Favorite

Changes to Pregnancy and Lactation Risk Labeling for Prescription Drugs

By  

NURSING FOR WOMENS HEALTH, Vol. 19, Iss. 3, 2015-06 ,pp. : 266-270

John Wiley & Sons Inc

Access to resources Recommend Favorite

Labeling

By  

THE BROWN UNIVERSITY PSYCHOPHARMACOLOGY UPDATE, Vol. 26, Iss. 6, 2015-06 ,pp. : 8-8

John Wiley & Sons Inc

Access to resources Recommend Favorite

New Horny Layer Marker Proteins for Evaluating Skin Condition in Atopic Dermatitis

By  

International Archives of Allergy and Immunology, Vol. 150, Iss. 1, 2009-04 ,pp. : 89-101

Karger

Access to resources Recommend Favorite